{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(12)"],"submitter":["Kook HW"],"pubmed_abstract":["<b>Background</b>: Unlike therapy-related myeloid neoplasms, therapy-related acute lymphoblastic leukaemia (tr-ALL) is poorly defined due to its rarity. However, increasing reports have demonstrated that tr-ALL is a distinct entity with adverse genetic features and clinical outcomes. <b>Methods:</b> We compared the clinicopathological characteristics and outcomes of patients diagnosed with tr-ALL (<i>n</i> = 9) or <i>de novo</i> ALL (dn-ALL; <i>n</i> = 162) at a single institution from January 2012 to March 2021. The mutational landscapes of eight tr-ALL and 63 dn-ALL patients were compared from a comprehensive next-generation sequencing panel. <b>Results</b>: All tr-ALL patients had the B-cell phenotype. The most frequently mutated genes were <i>IKZF1</i> (37%), <i>CDKN2A</i> (14%), <i>SE"],"journal":["Journal of Cancer"],"pagination":["3326-3332"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9516015"],"repository":["biostudies-literature"],"pubmed_title":["Therapy-related Acute Lymphoblastic Leukaemia has a Unique Genetic Profile Compared to <i>De Novo</i> Acute Lymphoblastic Leukaemia."],"pmcid":["PMC9516015"],"pubmed_authors":["Shin S","Min YH","Kim JJ","Kook HW","Cheong JW","Park MR","Jang JE","Lee ST"],"additional_accession":[]},"is_claimable":false,"name":"Therapy-related Acute Lymphoblastic Leukaemia has a Unique Genetic Profile Compared to <i>De Novo</i> Acute Lymphoblastic Leukaemia.","description":"<b>Background</b>: Unlike therapy-related myeloid neoplasms, therapy-related acute lymphoblastic leukaemia (tr-ALL) is poorly defined due to its rarity. However, increasing reports have demonstrated that tr-ALL is a distinct entity with adverse genetic features and clinical outcomes. <b>Methods:</b> We compared the clinicopathological characteristics and outcomes of patients diagnosed with tr-ALL (<i>n</i> = 9) or <i>de novo</i> ALL (dn-ALL; <i>n</i> = 162) at a single institution from January 2012 to March 2021. The mutational landscapes of eight tr-ALL and 63 dn-ALL patients were compared from a comprehensive next-generation sequencing panel. <b>Results</b>: All tr-ALL patients had the B-cell phenotype. The most frequently mutated genes were <i>IKZF1</i> (37%), <i>CDKN2A</i> (14%), <i>SE","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-22T03:41:24.75Z","creation":"2025-04-05T20:46:49.744Z"},"accession":"S-EPMC9516015","cross_references":{"pubmed":["36186901"],"doi":["10.7150/jca.76719"]}}